New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Cytokinetics, Incorporated
CYTK
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

6B

Biotechnology

Next Earning date - 25 Feb 2025

6B

Biotechnology

Next Earning date - 25 Feb 2025

51.86USD
Shape-0.36 ( -0.69%)
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

-66%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

53%

Quote Panel

Shape
Updated December 2, 2024
1W -0.31 % 1M 0.74 % 3M -4.95 % 1Y 53.02 %

Key Metrics

Shape
  • Market Cap

    6.12B


  • Shares Outstanding

    118.01M


  • Share in Float

    113.60M


  • Dividende

    0


  • Earning Date

    25 Feb 2025


  • Price Target

    51.86


  • Average Volume

    1.25M


  • Beta

    0.783


  • Range

    32.39-110.25


  • Industry

    Biotechnology


  • Website

    https://www.cytokinetics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

1901.28x

P/S Ratio

-438.73x

P/B Ratio

-48.5

Debt/Equity

-17906.2%

Net Margin

$-5.4

EPS

How CYTK compares to sector?

P/E Ratio

Relative Strength

Shape

CYTK

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$51M

Shape10819%

2025-Revenue

$5.37

Shape-295%

2025-EPS

$51M

Shape63%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Goldman Sachs

downgrade

Previous: Not converted

2024-08-13

Now: Neutral

Oppenheimer

initialise

Previous: Not converted

2023-08-15

Now: Outperform

Barclays

initialise

Previous: Not converted

2023-08-15

Now: Overweight

Cantor Fitzgerald

initialise

Previous: Not converted

2023-08-15

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

N/A

-1.45
vs -0.36

Q1.23

arrow
arrow

N/A

-1.38
vs -1.02

Q2.23

arrow
arrow

N/A

-1.34
vs -0.23

Q3.23

arrow
arrow

N/A

-1.35
vs -1.28

Q4.23

arrow
arrow

N/A

-1.38
vs -1.45

Q1.24

arrow
arrow

N/A

-1.33
vs -1.38

Q2.24

arrow
arrow

N/A

-1.31
vs -1.34

Q3.24

arrow
arrow

N/A

-1.36
vs -1.35

Q4.24

arrow
arrow

N/A

-1.25
vs -1.38

Q1.25

arrow
arrow

N/A

-1.27
vs -1.33

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

-96%

2M  vs 55.6M

Q1.23

arrow
arrow

+302%

4.6M  vs 1.1M

Q2.23

arrow
arrow

-99%

867K  vs 89M

Q3.23

arrow
arrow

-85%

378K  vs 2.5M

Q4.23

arrow
arrow

-15%

1.7M  vs 2M

Q1.24

arrow
arrow

-82%

835K  vs 4.6M

Q2.24

arrow
arrow

-71%

249K  vs 867K

Q3.24

arrow
arrow

+22%

463K  vs 378K

Q4.24

arrow
arrow

+514%

10.3M  vs 1.7M

Q1.25

arrow
arrow

-39%

508K  vs 835K

Return on EquityShape

status-upQoQ

Q4.22

arrow
arrow

+122%

1.22
vs 11.03

Q1.23

arrow
arrow

+57%

0.57
vs 1.22

Q2.23

arrow
arrow

+39%

0.39
vs 0.57

Q3.23

arrow
arrow

+29%

0.29
vs 0.39

Q4.23

arrow
arrow

+35%

0.35
vs 0.29

Q1.24

arrow
arrow

+34%

0.34
vs 0.35

Q2.24

arrow
arrow

-132%

-1.32
vs 0.34

Q3.24

arrow
arrow

+1154%

11.54
vs -1.32

Institutionnal OwnershipShape

status-upQoQ

Q4.22

arrow
arrow

293

293
vs 292

0%

Q1.23

arrow
arrow

271

271
vs 293

-8%

Q2.23

arrow
arrow

268

268
vs 271

-1%

Q3.23

arrow
arrow

281

281
vs 268

5%

Q4.23

arrow
arrow

427

427
vs 281

52%

Q1.24

arrow
arrow

454

454
vs 427

6%

Q2.24

arrow
arrow

389

389
vs 454

-14%

Q3.24

arrow
arrow

390

390
vs 389

0%

Earnings Growth

Latest News